{"organizations": [], "uuid": "9b29c8ecd4ece105bec8c068c7edd5d7afdfc70c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/15/business-wire-eagle-pharmaceuticals-inc-to-discuss-fourth-quarter-and-year-end-2017-financial-results-on-february-26-2018.html", "country": "US", "domain_rank": 767, "title": "Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-16T00:30:00.000+02:00", "replies_count": 0, "uuid": "9b29c8ecd4ece105bec8c068c7edd5d7afdfc70c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/15/business-wire-eagle-pharmaceuticals-inc-to-discuss-fourth-quarter-and-year-end-2017-financial-results-on-february-26-2018.html", "ord_in_thread": 0, "title": "Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018", "locations": [], "entities": {"persons": [{"name": "pete meyers", "sentiment": "none"}, {"name": "scott tarriff", "sentiment": "none"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "woodcliff lake", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "nasd", "sentiment": "neutral"}, {"name": "eagle pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "eagle", "sentiment": "none"}, {"name": "about eagle pharmaceuticals, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (\"Eagle\" or “the Company”) (Nasdaq: EGRX) today announced that the Company will release its 2017 fourth quarter and full year financial results on Monday, February 26, 2018, before the market opens.\nScott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:\nDate Monday, February 26, 2018 Time 8:30 a.m. EST Toll free (U.S.) 866-518-6930 International 203-518-9797 Webcast (live and replay) www.eagleus.com , under the “Investor Relations” section\nA replay of the conference call will be available for one week after the call's completion by dialing 800-677-7320 (US) or 402-220-0666 (International) and entering conference call ID EGRXQ417. The webcast will be archived for 30 days at the aforementioned URL.\nAbout Eagle Pharmaceuticals, Inc.\nEagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com .\n //www.businesswire.com/news/home/20180215005283/en/\nInvestor Relations for Eagle Pharmaceuticals, Inc:\nLisa M. Wilson, 212-452-2793\nlwilson@insitecony.com\nSource: Eagle Pharmaceuticals, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eagleus.com%2F&esheet=51759248&newsitemid=20180215005283&lan=en-US&anchor=www.eagleus.com&index=1&md5=3b120958095ad61bf9800223a6e51f19", "http://www.businesswire.com/news/home/20180215005283/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eagleus.com&esheet=51759248&newsitemid=20180215005283&lan=en-US&anchor=www.eagleus.com&index=2&md5=c97c49c1bdacff8ffdde3f2ad838ef3d"], "published": "2018-02-16T00:30:00.000+02:00", "crawled": "2018-02-16T03:33:32.011+02:00", "highlightTitle": ""}